IRVINE, Calif., Aug. 9, 2012 /PRNewswire/ -- ChromaDex ® Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries announced today that the human clinical data for its patented pTeroPure® (pterostilbene) study was accepted for presentation at the High Blood Pressure Research 2012 Scientific Sessions, sponsored by the American Heart Association's Council for High Blood Pressure Research and Council on Kidney in Cardiovascular Disease. The presentation will be September 20, 2012, in Washington, D.C.
The study — an eight week, double-blind, randomized, placebo-controlled trial — included 80 adults who were given either a placebo or 100 milligrams or 250 milligrams of pTeroPure per day to evaluate pTeroPure's effects on blood pressure, weight loss and cholesterol. Led by principle investigator Dr. Daniel Riche, PharmD, Cardiometabolic Clinic Coordinator at the University of Mississippi School of Pharmacy, the study was a collaboration between the University of Mississippi and ChromaDex.
"We are proud to be able to present the efficacy results for pterostilbene at the American Heart Association Scientific Sessions. Pterostilbene is a promising ingredient in the area of cardiometabolics," said Dr. Riche. "The study's endpoints of blood pressure, weight and cholesterol are important health parameters for most Americans and ones that I manage for my patients on a daily basis."The safety data from the clinical trial was previously presented at the 6th World Congress on Polyphenols Applications in Paris, France, on June 7, 2012. The results showed a lack of adverse reactions with no major adverse events supporting the safety of pterostilbene. "Presentation of the pTeroPure human clinical data is a significant milestone for ChromaDex. Being accepted by the American Heart Association to present at this nationally renowned meeting, which focuses on blood pressure, is an outstanding platform to showcase the benefits of this amazing ingredient," said Frank Jaksch, Jr., CEO and co-founder of ChromaDex. "We believe this milestone will allow ChromaDex to advance numerous business development opportunities to monetize its exclusive worldwide patent rights for pTeroPure in both the vast over-the-counter and pharmaceutical markets." Pterostilbene is an antioxidant found in blueberries and other berries and is believed by many experts to have a number of health benefits. Pterostilbene has superior biological activity , , , , , better oral bioavailability , ,  and metabolizes more slowly in the body than other antioxidant polyphenols (substances from plants that tend to prevent or neutralize the damaging effects of free radicals), resulting in more prolonged antioxidant activity , , , . Along with a number of other effects, pterostilbene has shown great promise for supporting heart health , , , ,  , cognitive function ,  and anti-aging , . pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. About ChromaDex ®: ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure ® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694 Forward-Looking Statements: Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts